FDA approves ramucirumab plus erlotinib for first-line metastatic …
WEBOn May 29, 2020, the Food and Drug Administration approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell...
Pembrolizumab Plus Ramucirumab Yields Improved Survival Vs …
WEBJun 3, 2022 · The combination of pembrolizumab plus ramucirumab resulted in better overall survival compared with the standard of care regimens despite similar response rates, according to results of a Lung-MAP substudy presented at 2022 ASCO.
Ramucirumab - Wikipedia
WEBRamucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre …
Ramucirumab plus erlotinib in patients with untreated,
WEBOct 4, 2019 · Ramucirumab plus erlotinib demonstrated superior progression-free survival compared with placebo plus erlotinib in patients with untreated EGFR-mutated metastatic NSCLC. Safety was consistent with the safety profiles of the individual compounds in advanced lung cancer.
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as …
WEBMay 30, 2020 · CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the ...
Phase II Randomized Study of Ramucirumab and Pembrolizumab …
WEBJun 3, 2022 · Ramucirumab and pembrolizumab led to improved overall survival compared with standard of care in patients with advanced NSCLC previously treated with chemotherapy and immunotherapy with acquired resistance to prior ICI in this randomized phase II trial. Similar benefit was seen across subgroups.
Gemcitabine with or without ramucirumab as second-line …
WEBSep 6, 2021 · Ramucirumab plus gemcitabine significantly improved overall survival after first-line standard chemotherapy, with a favourable safety profile. This combination could be a new option in this setting.
Results of a phase II trial of ramucirumab plus irinotecan as …
WEBThe RAINBOW trial showed RAM plus paclitaxel (PTX) increased overall survival (OS) compared with PTX alone for advanced gastric cancer (AGC) in second-line treatment. WJOG 4007 trial demonstrated equivalent efficacy between irinotecan (IRI) and PTX.
Ramucirumab - NCI - National Cancer Institute
WEBUpdated: December 8, 2023. Ramucirumab works by blocking a protein called VEGFR-2, which some cancer cells produce in large amounts. Blocking VEGFR-2 may prevent the growth of new blood vessels that tumors need to grow. Ramucirumab is a type of targeted therapy drug called an angiogenesis inhibitor.
Predictive biomarkers for survival benefit with ramucirumab in ...
WEBThe RANGE study (NCT02426125) evaluated ramucirumab (an anti-VEGFR2 monoclonal antibody) in patients with platinum-refractory advanced urothelial carcinoma (UC).